European Companies Search Engine

Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

Genmab A/S, Valby, Denmark

Watch
Genmab A/S

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Premium Service
Unlock Dossier
What is a Dossier?
A dossier provides comprehensive company details as a PDF, together with all underlying original publications and original data in one place.
The download feature is exclusively available for our paid plan. Upgrade your account to access:
Quick Dossier
Entire company details as a PDF
Power Dossier
Entire company details along with all original publications / original data bundled in a ZIP file
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more
Learn more
View plans

Name

Genmab A/S
Gfkjus 519 ApS

Identification

Cvrcom
CVR 21023884
Stockp
GMAB GMAB.CO GNMSF
Lei
529900MTJPDPE4MHJ122
EUID
DKCVR.21023884

Address

Carl Jacobsens Vej 30, 2500 Valby, Denmark
København, Denmark

Corporate purpose

72.10.00
Research and experimental development on natural sciences and engineering

The purpose of the Company is to conduct medical research, production and sale of such products and other related activities.

Financial performance

History

Persons

Marketing & Tech

Network

Loading network

Legal Structure

Current legal representatives Legal form information Premium
Premium
1Chair of the board
1CEO
1Vice chair of the board
1Director
2Deputy member of the board
6Member of the board
1Auditor
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

DATA SERVICES

Unlock the full potential of processed company data with our API or Quarterly Exports.

Ownership relations Premium + Ownership & Flags add-on
Premium + Ownership & Flags add-on
Portfolio and Investments
3 known active shareholdings
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

Financials

Key Performance Indicators Financial · Mktg & Tech Premium
Premium
Base/share capital
Total assets
Earnings
Earnings CAGR
Revenue
Revenue CAGR
Return on sales
Equity
Equity ratio
Return on equity
Taxes
Tax ratio
Cash on hand
Receivables
Liabilities
Patents
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans
Annual report
 
Financial Statements Interactive sheets with CSV/Excel download Premium
Premium
Balance
from 2005 to 2025
Profit & Loss
from 2005 to 2025
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

Publications

6 Nov 2026
Annual report for the year ending 30/09/2026
29 Sept 2026
Company statute
28 Sept 2026
Shareholder: Darwin Global Management Ltd. · Voting rights: Darwin Global Management Ltd
9 Sept 2026
Capital: 62.4M DKK · Company statute
17 Aug 2026
Dismissed: Michael A. Kavanagh
15 Aug 2026
Member of the board: Gina Th. Schweizer
14 Aug 2026
No longer Deputy member of the board: Gina Th. Schweizer
14 Aug 2026
No longer Member of the board: Michael A. Kavanagh
12 Aug 2026
Capital: 62.4M DKK · Company statute
10 Aug 2026
Annual report for the year ending 30/06/2026
17 Jun 2026
Capital: 62.4M DKK · Company statute
15 Jun 2026
Company statute
13 May 2026
Capital: 62.4M DKK · Company statute
8 May 2026
Annual report for the year ending 31/03/2026
30 Apr 2026 via Genmab Iberia SL
Proprietor: Genmab Iberia SL
29 Apr 2026
Patent: Multispecific antibodies against CD40 and CD137
17 Apr 2026
Capital: 62.4M DKK · Company statute
31 Mar 2026
Annual report for the year ending 31/12/2025
23 Mar 2026
Company statute
19 Mar 2026
Capital: 1,900,000 DKK
4 Mar 2026
Company statute
25 Feb 2026
Capital: 64.3M DKK · Company statute
17 Feb 2026
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
3 Feb 2026
Company statute
17 Jan 2026
European Union Transparency Register
4 Jan 2026 via Genmab France SAS
President: Genmab France SAS
31 Dec 2025
Balance sheet for 31/12/2025 · Earnings statement for 31/12/2025
Year 2025 in Epobase
8 European patent filings: Humanized or Chimeric CD3 Antibodies …
26 Dec 2025 via Genmab France SAS
President: Genmab France SAS
26 Nov 2025
Company statute
19 Nov 2025
Capital: 64.2M DKK · Company statute
11 Nov 2025
Annual report for the year ending 30/09/2025
17 Oct 2025
Annual report for the year ending 30/06/2025
30 Sept 2025
Company statute
10 Sept 2025
Capital: 64.2M DKK · Company statute
13 Aug 2025
Annual report for the year ending 30/06/2025
13 Aug 2025
Capital: 64.2M DKK · Company statute
7 Aug 2025
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
30 Jul 2025 via Genmab France SAS
President: Genmab France SAS
18 Jun 2025
Capital: 64.2M DKK · Company statute
16 Jun 2025
Company statute
21 May 2025
Capital: 64.1M DKK · Company statute
14 May 2025
Annual report for the year ending 31/03/2025
10 Apr 2025
Capital: 64.1M DKK · Company statute
20 Mar 2025
Persons · Company statute
13 Mar 2025
Annual report for the year ending 31/12/2024
12 Mar 2025
No longer Deputy member of the board: Julie Blædel
12 Mar 2025
No longer Deputy member of the board: Richard G. Hibbert
12 Mar 2025
No longer Member of the board: Takahiro Hamatani
12 Mar 2025
Deputy member of the board: Ogi Takahashi
12 Mar 2025
Deputy member of the board: Gina Th. Schweizer
12 Mar 2025
Member of the board: Michael A. Kavanagh
12 Mar 2025
Deputy member of the board: M. Ramirez-Andersen
12 Mar 2025
Capital: 2,076,853 DKK
6 Mar 2025
Company statute
26 Feb 2025
Capital: 66.2M DKK · Company statute
12 Feb 2025
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
29 Jan 2025
Company statute
31 Dec 2024
Balance sheet for 31/12/2024 · Earnings statement for 31/12/2024
Year 2024 in Epobase
30 European patent filings: Anti-Psma Conjugates and Methods of Using the Same …
4 Dec 2024
Capital: 66.2M DKK · Company statute
27 Nov 2024
Company statute
20 Nov 2024
Annual report for the year ending 30/09/2024
14 Oct 2024
Annual report for the year ending 30/06/2024
1 Oct 2024
Company statute
11 Sept 2024
Capital: 66.2M DKK · Company statute
29 Aug 2024
Annual report for the year ending 30/06/2024
14 Aug 2024
Capital: 66.2M DKK · Company statute
8 Aug 2024
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
19 Jun 2024
Capital: 66.1M DKK · Company statute
17 Jun 2024
Company statute
12 Jun 2024
Wordmark: “ABBIL1TY“
12 May 2024
Annual report for the year ending 31/03/2024
8 May 2024
Capital: 66.1M DKK · Company statute
21 Mar 2024
Auditor: Deloitte Statsautoriseret P/S · No longer Auditor: Pricewaterhousecoopers Statsautoriseret P/S · Company statute
13 Mar 2024
Annual report for the year ending 31/12/2023
13 Mar 2024
No longer Auditor: Pricewaterhousecoopers Statsautoriseret P/S
13 Mar 2024
Auditor: Deloitte Statsautoriseret P/S
28 Feb 2024
Capital: 66.1M DKK · Company statute
26 Feb 2024
Company statute
14 Feb 2024
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
31 Jan 2024
Company statute
31 Dec 2023
Balance sheet for 31/12/2023 · Earnings statement for 31/12/2023
20 Dec 2023
Dismissed: Suzana S. Couto
Year 2023 in Euipotm
7 trademark filings (5 wordmarks, 2 word figurative marks): FORTYSSIMO, Rina-S, We are extra(not)ordinary, extra[not]ordinary …
13 Dec 2023
Capital: 66.1M DKK · Company statute
1 Dec 2023
Company statute
Year 2023 in Epobase
12 European patent filings: Multispecific Antibody Against CD40 and CD137 in Combination Therapy with Anti-PD1 AB and Chemotherapy …
13 Nov 2023
Annual report for the year ending 30/09/2023
8 Nov 2023
Change of shareholdings: Wellington Management Group LLP · Voting rights: Wellington Management Group LLP
5 Oct 2023
Company statute
13 Sept 2023
Capital: 66.1M DKK · Company statute
16 Aug 2023
Annual report for the year ending 30/06/2023
16 Aug 2023
Capital: 66.1M DKK · Company statute
3 Aug 2023
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
31 Jul 2023
Address
21 Jun 2023
Capital: 66M DKK · Company statute
19 Jun 2023
Company statute
1 Jun 2023
Annual report for the year ending 31/03/2023
24 May 2023
Capital: 66M DKK · Company statute
10 Apr 2023
No longer Deputy member of the board: Suzana S. Couto
3 Apr 2023
Company statute
30 Mar 2023
Annual report for the year ending 31/12/2022
13 Mar 2023
Danish company filing
1 Mar 2023
Capital: 66M DKK · Company statute
27 Feb 2023
Company statute
22 Feb 2023
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
30 Jan 2023
Company statute
9 Jan 2023
No longer Director: Anthony Mancini
1 Jan 2023
No longer Director (1)
1 Jan 2023
No longer Director: Anthony Mancini
1 Jan 2023
No longer Director: Tahamtan Ahmadi
31 Dec 2022
Balance sheet for 31/12/2022 · Earnings statement for 31/12/2022
14 Dec 2022
Capital: 66M DKK · Company statute
29 Nov 2022
Company statute
18 Nov 2022
Annual report for the year ending 30/09/2022
16 Nov 2022
Capital: 65.9M DKK · Company statute
Year 2022 in Epobase
14 European patent filings: Multispecific Binding Agents Against PD-L1 and CD137 in Combination with Anti PD-1 Antibodies for Treating Cancers …
4 Oct 2022
Change of shareholdings: Wellington Management Group LLP · Voting rights: Wellington Management Group LLP
29 Sept 2022
Wordmark: “KYSO antibodies“
28 Sept 2022
Capital: 65.8M DKK · Company statute
28 Sept 2022
Wordmark: “KYSO antibody medicines“
23 Sept 2022
Company statute
22 Aug 2022
Annual report for the year ending 30/06/2022
17 Aug 2022
Capital: 65.8M DKK · Company statute
10 Aug 2022
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
1 Aug 2022
Change of shareholdings: Wellington Management Group LLP · Voting rights: Wellington Management Group LLP
8 Jul 2022
Change of shareholdings: Wellington Management Group LLP · Voting rights: Wellington Management Group LLP
6 Jul 2022
Capital: 65.8M DKK · Company statute
30 Jun 2022
Change of shareholdings: Wellington Management Group LLP · Voting rights: Wellington Management Group LLP
16 Jun 2022
Company statute
3 Jun 2022
Wordmark: “KYSO“
27 May 2022
Change of shareholdings: Wellington Management Group LLP · Voting rights: Wellington Management Group LLP
18 May 2022
Capital: 65.8M DKK · Company statute
17 May 2022
Annual report for the year ending 31/03/2022
7 Apr 2022
Company statute
6 Apr 2022
Member of the board: E. Grimes O'Farrell
30 Mar 2022
Annual report for the year ending 31/12/2021
29 Mar 2022
Deputy member of the board: Julie Blædel
29 Mar 2022
Member of the board: Martin Schultz
29 Mar 2022
No longer Member of the board: Peter S. Kristensen
29 Mar 2022
No longer Member of the board: Rima Bawarshi Nassar
29 Mar 2022
No longer Deputy member of the board: Simone de Haij
29 Mar 2022
No longer Deputy member of the board: Nina Holst
29 Mar 2022
Deputy member of the board: Suzana S. Couto
29 Mar 2022
Deputy member of the board: Richard G. Hibbert
29 Mar 2022
Member of the board: E. Grimes O'Farrell
29 Mar 2022
Member of the board: Takahiro Hamatani
9 Mar 2022
Company statute
23 Feb 2022
Capital: 65.7M DKK · Company statute
16 Feb 2022
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
3 Feb 2022
Company statute
31 Dec 2021
Balance sheet for 31/12/2021 · Earnings statement for 31/12/2021
Year 2021 in Epobase
19 European patent filings: Modified Immunoglobulin with Affinity for Fcgammariib and Method of USE Thereof …
15 Dec 2021
Capital: 65.7M DKK · Company statute
30 Nov 2021
Company statute
19 Nov 2021
Annual report for the year ending 30/09/2021
17 Nov 2021
Capital: 65.7M DKK · Company statute
16 Nov 2021
No longer Member of the board: Jonathan M. Peacock
15 Nov 2021
No longer Member of the board: Jonathan M. Peacock
15 Oct 2021
Company statute
22 Sept 2021
Capital: 65.7M DKK · Company statute
19 Aug 2021
Annual report for the year ending 30/06/2021
18 Aug 2021
Capital: 65.7M DKK · Company statute
11 Aug 2021
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
16 Jul 2021
Change of shareholdings: Artisan Partners LP · Voting rights: Artisan Partners LP
7 Jul 2021
Capital: 65.7M DKK · Company statute
1 Jul 2021
Company statute
16 May 2021
Annual report for the year ending 31/03/2021
12 May 2021
Capital: 65.6M DKK · Company statute
5 May 2021
Patent: Humane Monoklonale Antikörper Gegen CD20
26 Apr 2021
Company statute
19 Apr 2021
Annual report for the year ending 31/12/2020
15 Apr 2021
Annual report for the year ending 31/12/2020
3 Mar 2021
Capital: 65.6M DKK · Company statute
2 Mar 2021
Company statute
1 Mar 2021
Director: Tahamtan Ahmadi
1 Mar 2021
Director: Tahamtan Ahmadi
23 Feb 2021
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
5 Feb 2021
Company statute
31 Dec 2020
Balance sheet for 31/12/2020 · Earnings statement for 31/12/2020
21 Dec 2020
Company statute
15 Nov 2020
Annual report for the year ending 30/09/2020
11 Nov 2020
Capital: 65.5M DKK · Company statute
Year 2020 in Epobase
8 European patent filings: Methods of Treating Cancer with a Combination of a Platinum-Based Agent and an Anti-Tissue Factor Antibody-Drug Conjugate …
26 Oct 2020
Patent: Antikörper Gegen CD38 zur Behandlung von Multiplem Myelom
15 Oct 2020
Company statute
30 Sept 2020
Capital: 65.5M DKK · Company statute
28 Aug 2020
Annual report for the year ending 30/06/2020
25 Aug 2020
Dismissed: Daniel John Bruno
19 Aug 2020
Capital: 65.4M DKK · Company statute
17 Aug 2020
No longer Member of the board: Daniel John Bruno
17 Aug 2020
Member of the board: Rima Bawarshi Nassar
16 Aug 2020
No longer Deputy member of the board: Rima Bawarshi Nassar
12 Aug 2020
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
14 Jul 2020
Change of shareholdings: Société Générale SA · Voting rights: Société Générale SA
2 Jul 2020
Change of shareholdings: Société Générale SA · Voting rights: Société Générale SA
1 Jul 2020
Change of shareholdings: Société Générale SA · Voting rights: Société Générale SA
1 Jul 2020
Capital: 65.3M DKK · Company statute
29 Jun 2020
Change of shareholdings: Société Générale SA · Voting rights: Société Générale SA
11 Jun 2020
Company statute
29 May 2020
Annual report for the year ending 31/03/2020
13 May 2020
Capital: 65.3M DKK · Company statute
1 Apr 2020
Capital: 65.2M DKK · Company statute
30 Mar 2020
Member of the board: Pernille Erenbjerg · Company statute
30 Mar 2020
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
26 Mar 2020
Annual report for the year ending 31/12/2019
26 Mar 2020
Vice chair of the board: Pernille Erenbjerg
26 Mar 2020
No longer Chair of the board: Mats G. Pettersson
26 Mar 2020
Chair of the board: Deirdre P. Connelly
26 Mar 2020
Member of the board: Jonathan M. Peacock
25 Mar 2020
No longer Member of the board: Pernille Erenbjerg
25 Mar 2020
No longer Vice chair of the board: Deirdre P. Connelly
23 Mar 2020
Director: Anthony Mancini
23 Mar 2020
Director: Anthony Mancini
2 Mar 2020
Director: Anthony M. Pagano · No longer Director: David Andrew Eatwell
1 Mar 2020
No longer Director: David Andrew Eatwell
1 Mar 2020
Director: Anthony M. Pagano
26 Feb 2020
Capital: 65.2M DKK · Company statute
31 Dec 2019
Balance sheet for 31/12/2019 · Earnings statement for 31/12/2019
Year 2019 in Epobase
27 European patent filings: Humanized or Chimeric CD3 Antibodies …
17 Dec 2019
Company statute
13 Nov 2019
Annual report for the year ending 30/09/2019
13 Nov 2019
Capital: 65.1M DKK · Company statute
22 Oct 2019
Company statute
2 Oct 2019
Capital: 65M DKK · Company statute
28 Aug 2019
Annual report for the year ending 30/06/2019
21 Aug 2019
Capital: 65M DKK · Company statute
14 Aug 2019
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
23 Jul 2019
Capital: 65M DKK · Company statute
22 Jul 2019
Capital: 64.5M DKK · Company statute
18 Jul 2019
Shareholder: Blackrock Inc. · Voting rights: Blackrock Inc
26 Jun 2019
Capital: 61.7M DKK · Company statute
21 Jun 2019
Change of shareholdings: Blackrock Inc. · Voting rights: Blackrock Inc
18 Jun 2019
Change of shareholdings: Blackrock Inc. · Voting rights: Blackrock Inc
17 Jun 2019
Change of shareholdings: Blackrock Inc. · Voting rights: Blackrock Inc
14 Jun 2019
Change of shareholdings: Blackrock Inc. · Voting rights: Blackrock Inc
13 Jun 2019
Company statute
21 May 2019
Annual report for the year ending 31/03/2019
15 May 2019
Capital: 61.7M DKK · Company statute
3 Apr 2019
Capital: 61.7M DKK · Company statute
2 Apr 2019
Persons · Company statute
29 Mar 2019
Annual report for the year ending 31/12/2018
22 Mar 2019
No longer Deputy member of the board: Stephen Paul Bryant
22 Mar 2019
No longer Member of the board: Richard G. Hibbert
22 Mar 2019
Deputy member of the board: Rima Bawarshi Nassar
22 Mar 2019
Deputy member of the board: Simone de Haij
22 Mar 2019
Member of the board: Mijke Zachariasse
22 Mar 2019
Deputy member of the board: Nina Holst
8 Mar 2019
Company statute
27 Feb 2019
Capital: 61.5M DKK · Company statute
31 Jan 2019
Wordmark: “LYNXTIV“
31 Dec 2018
Balance sheet for 31/12/2018 · Earnings statement for 31/12/2018
17 Dec 2018
Company statute
27 Nov 2018
Annual report for the year ending 30/09/2018
21 Nov 2018
Capital: 61.5M DKK · Company statute
Year 2018 in Epobase
8 European patent filings: Anti-Tissue Factor Antibody-Drug Conjugates and Their USE in the Treatment of Cancer …
3 Oct 2018
Company statute
19 Sept 2018
Capital: 61.5M DKK · Company statute
28 Aug 2018
Annual report for the year ending 30/06/2018
15 Aug 2018
Capital: 61.5M DKK · Company statute
8 Aug 2018
Change of shareholdings: Blackrock Inc. · Voting rights: Blackrock Inc
4 Jul 2018
Capital: 61.5M DKK · Company statute
18 Jun 2018
Company statute
5 Jun 2018
Annual report for the year ending 31/03/2018
16 May 2018
Member of the board (1) · Capital: 61.4M DKK · Company statute
19 Apr 2018
Company statute
19 Apr 2018
Wordmark: “ABVANTEC“
19 Apr 2018
Wordmark: “ABVENTEC“
19 Apr 2018
Wordmark: “VENZIOV“
10 Apr 2018
Annual report for the year ending 31/12/2017
10 Apr 2018
Member of the board: Anders G. Pedersen
10 Apr 2018
Vice chair of the board: Deirdre P. Connelly
9 Apr 2018
No longer Vice chair of the board: Anders G. Pedersen
9 Apr 2018
No longer Member of the board: Deirdre P. Connelly
4 Apr 2018
Capital: 61.3M DKK · Company statute
1 Mar 2018
Capital: 61.3M DKK · Company statute
5 Jan 2018
Change of shareholdings: Artisan Partners LP · Voting rights: Artisan Partners LP
31 Dec 2017
Balance sheet for 31/12/2017 · Earnings statement for 31/12/2017
21 Dec 2017
Company statute
15 Nov 2017
Capital: 61.2M DKK · Company statute
13 Nov 2017
Annual report for the year ending 30/09/2017
9 Nov 2017
Change of shareholdings: Blackrock Inc. · Voting rights: Blackrock Inc
2 Nov 2017
Dismissed: Pernille Hemmingsen
31 Oct 2017
No longer Deputy member of the board: Pernille Hemmingsen
13 Oct 2017
Company statute
27 Sept 2017
Capital: 61.2M DKK · Company statute
Year 2017 in Epobase
10 European patent filings: Modulation of Complement-Dependent Cytotoxicity through Modifications of the C-Terminus of Antibody Heavy Chains …
17 Aug 2017
Annual report for the year ending 30/06/2017
16 Aug 2017
Capital: 61.1M DKK · Company statute
28 Jun 2017
Capital: 61.1M DKK · Company statute
19 Jun 2017
Address
15 Jun 2017
Company statute
17 May 2017
Capital: 61M DKK · Company statute
16 May 2017
Annual report for the year ending 31/03/2017
5 Apr 2017
Capital: 60.9M DKK · Company statute
3 Apr 2017
Member of the board: Deirdre P. Connelly · No longer Member of the board: Burton G. Malkiel · Dismissed: Tom Vink · Company statute
31 Mar 2017
No longer Deputy member of the board: Tom Vink
29 Mar 2017
Annual report for the year ending 31/12/2016
28 Mar 2017
No longer Member of the board: Burton G. Malkiel
28 Mar 2017
Member of the board: Rolf K. H. Hoffmann
28 Mar 2017
Member of the board: Deirdre P. Connelly
1 Mar 2017
Capital: 60.7M DKK · Company statute
15 Feb 2017
Director (1) · Company statute
13 Feb 2017
Director (1)
19 Jan 2017
Patent: AXL-Spezifische Antikörper-Wirkstoff-Konjugate zur Krebsbehandlung
19 Jan 2017
Patent: AXL-Spezifische Antikörper-Wirkstoff-Konjugate zur Krebsbehandlung
1 Jan 2017
Wordmark: “HUMAX-CD20“
31 Dec 2016
Balance sheet for 31/12/2016 · Earnings statement for 31/12/2016
21 Dec 2016
Company statute
11 Nov 2016
Annual report for the year ending 30/09/2016
10 Nov 2016
Capital: 60.4M DKK · Company statute
Year 2016 in Epobase
11 European patent filings: IGG4 Antibody Variants Having Modifications in the Constant Region …
11 Oct 2016
Company statute
28 Sept 2016
Capital: 60.2M DKK · Company statute
8 Sept 2016
Change of shareholdings: FMR LLC (Fidelity Management and Research) · Voting rights: FMR LLC (Fidelity Management and Research)
23 Aug 2016
Annual report for the year ending 30/06/2016
18 Aug 2016
Capital: 60.2M DKK · Company statute
14 Jul 2016
Patent: Agonistische TNF-Rezeptor-Bindungswirkstoffe
14 Jul 2016
Patent: Agonistische TNF-Rezeptor-Bindungswirkstoffe
14 Jul 2016
Patent: Agonistische TNF-Rezeptor-Bindungswirkstoffe
14 Jun 2016
Company statute
19 May 2016
Capital: 59.8M DKK · Company statute
13 May 2016
Annual report for the year ending 31/03/2016
2 May 2016
Persons · Proxy policy · Company statute
18 Mar 2016
Annual report for the year ending 31/12/2015
17 Mar 2016
No longer Member of the board (1)
17 Mar 2016
Deputy member of the board: Tom Vink
17 Mar 2016
No longer Deputy member of the board (1)
17 Mar 2016
Deputy member of the board: Pernille Hemmingsen
17 Mar 2016
Deputy member of the board: Stephen Paul Bryant
17 Mar 2016
Member of the board: Daniel John Bruno
17 Mar 2016
Member of the board: Richard G. Hibbert
17 Mar 2016
Member of the board: Peter S. Kristensen
16 Mar 2016
No longer Member of the board: Tom Vink
6 Mar 2016
Wordmark: “PROTEMBOR“
25 Feb 2016
Capital: 59.7M DKK · Company statute
3 Feb 2016
Change of shareholdings: Johnson & Johnson Innovation-JJDC Inc. · Voting rights: Johnson & Johnson Innovation-JJDC Inc
31 Dec 2015
Balance sheet for 31/12/2015 · Earnings statement for 31/12/2015
Year 2015 in Epobase
8 European patent filings: Prevention of Rash in Patients Undergoing Anti-Egfr Therapy …
18 Dec 2015
Company statute
16 Nov 2015
Change of shareholdings: FMR LLC (Fidelity Management and Research) · Voting rights: FMR LLC (Fidelity Management and Research)
15 Nov 2015
Change of shareholdings: FMR LLC (Fidelity Management and Research) · Voting rights: FMR LLC (Fidelity Management and Research)
12 Nov 2015
Capital: 59.5M DKK · Company statute
4 Nov 2015
Annual report for the year ending 30/09/2015
22 Oct 2015
Change of shareholdings: FMR LLC (Fidelity Management and Research) · Voting rights: FMR LLC (Fidelity Management and Research)
21 Oct 2015
Change of shareholdings: FMR LLC (Fidelity Management and Research) · Voting rights: FMR LLC (Fidelity Management and Research)
20 Oct 2015
Company statute
15 Oct 2015
Change of shareholdings: FMR LLC (Fidelity Management and Research) · Voting rights: FMR LLC (Fidelity Management and Research)
14 Oct 2015
Change of shareholdings: FMR LLC (Fidelity Management and Research) · Voting rights: FMR LLC (Fidelity Management and Research)
7 Oct 2015
Change of shareholdings: FMR LLC (Fidelity Management and Research) · Voting rights: FMR LLC (Fidelity Management and Research)
6 Oct 2015
Change of shareholdings: FMR LLC (Fidelity Management and Research) · Voting rights: FMR LLC (Fidelity Management and Research)
28 Sept 2015
Change of shareholdings: FMR LLC (Fidelity Management and Research) · Voting rights: FMR LLC (Fidelity Management and Research)
27 Sept 2015
Change of shareholdings: FMR LLC (Fidelity Management and Research) · Voting rights: FMR LLC (Fidelity Management and Research)
2 Sept 2015
Change of shareholdings: FMR LLC (Fidelity Management and Research) · Voting rights: FMR LLC (Fidelity Management and Research)
1 Sept 2015
Change of shareholdings: FMR LLC (Fidelity Management and Research) · Voting rights: FMR LLC (Fidelity Management and Research)
20 Aug 2015
Capital: 59.3M DKK · Company statute
12 Aug 2015
Annual report for the year ending 30/06/2015
9 Jul 2015
Change of shareholdings (1) · Voting rights (1)
23 Jun 2015
Company statute
21 Jun 2015
Wordmark: “HUMAX CD4“
21 May 2015
Capital: 58.7M DKK · Company statute
18 May 2015
Annual report for the year ending 31/03/2015
1 Apr 2015
Member of the board: Pernille Erenbjerg · No longer Member of the board (1) · Company statute
28 Mar 2015
Annual report for the year ending 31/12/2014
26 Mar 2015
Member of the board: Pernille Erenbjerg
26 Mar 2015
No longer Member of the board (1)
26 Mar 2015
Member of the board: Paolo A. Paoletti
12 Mar 2015
Capital: 58.1M DKK · Company statute
3 Feb 2015
Change of shareholdings: GlaxoSmithKline plc · Voting rights: GlaxoSmithKline plc
8 Jan 2015
Patent: Humanisierte oder Chimäre CD3-Antikörper
8 Jan 2015
Patent: Humanisierte oder Chimäre CD3-Antikörper
8 Jan 2015
Patent: Humanisierte oder Chimäre CD3-Antikörper
31 Dec 2014
Balance sheet for 31/12/2014 · Earnings statement for 31/12/2014
18 Dec 2014
Company statute
Year 2014 in Epobase
9 European patent filings: Human Monoclonal Antibodies to Epidermal Growth Factor Receptor (Egfr) …
25 Nov 2014
Annual report for the year ending 30/09/2014
13 Nov 2014
Capital: 57M DKK · Company statute
23 Oct 2014
Company statute
1 Oct 2014
Persons
30 Sept 2014
No longer Deputy member of the board (1)
2 Sept 2014
Annual report for the year ending 30/06/2014
21 Aug 2014
Capital: 56.8M DKK · Company statute
23 Jul 2014
Annual report for the year ending 31/03/2014
17 Jul 2014
Patent: Träges Format
17 Jul 2014
Patent: Träges Format
17 Jul 2014
Patent: Träges Format
16 Jun 2014
Company statute
15 May 2014
Capital: 56.7M DKK · Company statute
12 May 2014
Annual report for the year ending 31/12/2013
15 Apr 2014
Company statute
13 Mar 2014
Capital: 56.6M DKK · Company statute
11 Feb 2014
Company statute
29 Jan 2014
Change of shareholdings: Johnson & Johnson Innovation-JJDC Inc. · Voting rights: Johnson & Johnson Innovation-JJDC Inc
29 Jan 2014
Capital: 56.4M DKK · Company statute
31 Dec 2013
Balance sheet for 31/12/2013 · Earnings statement for 31/12/2013
12 Dec 2013
Company statute
10 Dec 2013
Change of shareholdings: FMR LLC (Fidelity Management and Research) · Voting rights: FMR LLC (Fidelity Management and Research)
22 Nov 2013
Annual report for the year ending 30/09/2013
14 Nov 2013
Capital: 51.8M DKK · Company statute
6 Nov 2013
Patent: Human Monoclonal Antibodies Against CD20
15 Oct 2013
Company statute
16 Sept 2013
Annual report for the year ending 30/06/2013
22 Aug 2013
Capital: 51.2M DKK · Company statute
18 Jun 2013
Company statute
24 May 2013
Annual report for the year ending 31/03/2013
16 May 2013
Annual report for the year ending 31/12/2012
16 May 2013
Capital: 51.1M DKK · Company statute
8 May 2013
Member of the board: Burton G. Malkiel
7 May 2013
Member of the board: Mats G. Pettersson · No longer Member of the board (2) · Company statute
22 Apr 2013
Word figurative mark: “Genmab“
17 Apr 2013
No longer Member of the board (1)
17 Apr 2013
Deputy member of the board (1)
17 Apr 2013
No longer Deputy member of the board (1)
17 Apr 2013
Vice chair of the board: Anders G. Pedersen
17 Apr 2013
No longer Deputy member of the board: Stephen Paul Bryant
17 Apr 2013
No longer Deputy member of the board (1)
17 Apr 2013
No longer Member of the board: Daniel John Bruno
17 Apr 2013
No longer Member of the board (1)
17 Apr 2013
No longer Vice chair of the board: Burton G. Malkiel · Member of the board: Burton G. Malkiel
17 Apr 2013
Chair of the board: Mats G. Pettersson
17 Apr 2013
Deputy member of the board (1)
17 Apr 2013
No longer Member of the board (1)
13 Mar 2013
Capital: 50.7M DKK · Company statute
13 Feb 2013
Company statute
24 Jan 2013
Change of shareholdings (1) · Voting rights (1)
31 Dec 2012
Balance sheet for 31/12/2012 · Earnings statement for 31/12/2012
Year 2012 in Epobase
5 European patent filings: Human Monoclonal Antibodies Against CD25 …
14 Dec 2012
Company statute
26 Nov 2012
Annual report for the year ending 30/09/2012
15 Nov 2012
Capital: 50.3M DKK · Company statute
16 Oct 2012
Capital: 50.3M DKK
10 Oct 2012
Company statute
9 Oct 2012
Address
6 Sept 2012
Annual report for the year ending 30/06/2012
9 Aug 2012
Patent: Menschliche Antikörper und Antikörper-Wirkstoff-Konjugate Gegen CD74
9 Aug 2012
Patent: Menschliche Antikörper und Antikörper-Wirkstoff-Konjugate Gegen CD74
9 Aug 2012
Patent: Menschliche Antikörper und Antikörper-Wirkstoff-Konjugate Gegen CD74
8 Jun 2012
Annual report for the year ending 31/03/2012
6 Jun 2012
Annual report for the year ending 31/12/2011
7 May 2012
Persons · Company statute
25 Apr 2012
Member of the board (1)
25 Apr 2012
Vice chair of the board: Burton G. Malkiel
31 Dec 2011
Balance sheet for 31/12/2011 · Earnings statement for 31/12/2011
21 Dec 2011
Company statute
25 Nov 2011
Annual report for the year ending 30/09/2011
Year 2011 in Epobase
12 European patent filings: Human Antibodies Specific for Interleukin 15 (IL-15) …
27 Oct 2011
Company statute
27 Sept 2011
Auditor: Pricewaterhousecoopers Statsautoriseret P/S · No longer Auditor: Pricewaterhousecoopers Services Statsautoriseret A/S
30 Aug 2011
Annual report for the year ending 30/06/2011
1 Jul 2011
Auditor: Pricewaterhousecoopers Statsautoriseret P/S
1 Jul 2011
No longer Auditor: Pricewaterhousecoopers Services Statsautoriseret A/S
1 Jul 2011
Company statute
10 Jun 2011
Annual report for the year ending 31/03/2011
5 May 2011
Annual report for the year ending 31/12/2010
19 Apr 2011
Member of the board (1) · Company statute
6 Apr 2011
Member of the board (1)
23 Mar 2011
Wordmark: “DUOBODY“
7 Jan 2011
Wordmark: “DUOBODY“
31 Dec 2010
Balance sheet for 31/12/2010 · Earnings statement for 31/12/2010
15 Dec 2010
Company statute
17 Nov 2010
Annual report for the year ending 30/09/2010
27 Oct 2010
Company statute
2 Sept 2010
Annual report for the year ending 30/06/2010
13 Jul 2010
Wordmark: “GENBRIA“
15 Jun 2010
No longer Director (1) · No longer Member of the board (1)
15 Jun 2010
No longer Director (1) · No longer Member of the board (1)
15 Jun 2010
Director: Jan van de Winkel
13 Jun 2010
Company statute
3 Jun 2010
Member of the board (2)
2 Jun 2010
Member of the board (1)
2 Jun 2010
Deputy member of the board (1)
2 Jun 2010
Deputy member of the board: Stephen Paul Bryant
2 Jun 2010
Deputy member of the board (1)
2 Jun 2010
Member of the board: Daniel John Bruno
2 Jun 2010
Member of the board: Tom Vink
27 May 2010
Annual report for the year ending 31/03/2010
10 May 2010
Annual report for the year ending 31/12/2009
4 May 2010
Company statute
26 Jan 2010
Patent: Methods for Producing Mixtures of Antibodies
6 Jan 2010
Company statute
31 Dec 2009
Balance sheet for 31/12/2009 · Earnings statement for 31/12/2009
9 Dec 2009
Patent: Human antibodies against human tissue factor
25 Nov 2009
Annual report for the year ending 30/09/2009
16 Oct 2009
Company statute
28 Aug 2009
Annual report for the year ending 30/06/2009
22 Jun 2009
Company statute
12 Jun 2009
Capital: 44.9M DKK · Company statute
2 Jun 2009
Annual report for the year ending 31/03/2009
5 May 2009
Annual report for the year ending 31/12/2008
30 Apr 2009
Patent: Neuartige Antikörpertherapien
23 Apr 2009
Company statute
16 Apr 2009
No longer Member of the board (1)
15 Apr 2009
No longer Member of the board (1)
8 Apr 2009
Patent: Prävention von Hautausschlag BEI Patienten in Anti-Egfr-Therapie
6 Mar 2009
Capital: 44.9M DKK · Company statute
20 Feb 2009
Patent: Methods for Assissing the Risk of Adverse Events Upon Treatment with IGG4 Antibodies
2 Feb 2009
Address
31 Dec 2008
Balance sheet for 31/12/2008 · Earnings statement for 31/12/2008
Year 2008 in Euipotm
4 trademark filings (3 wordmarks, 1 word figurative mark): EPTRIOR, UNIBODY …
23 Dec 2008
Company statute
17 Nov 2008
Annual report for the year ending 30/09/2008
7 Nov 2008
Capital: 44.9M DKK · Company statute
13 Oct 2008
Company statute
7 Oct 2008
Annual report for the year ending 30/06/2008
1 Oct 2008
Patent: Rekombinante Monovalente Antikörper und Herstellungsverfahren Dafür
30 Sept 2008
Change of shareholdings: GlaxoSmithKline plc · Voting rights: GlaxoSmithKline plc
8 Sept 2008
Capital: 44.7M DKK · Company statute
Year 2008 in Epobase
9 European patent filings: Novel Methods and Antibodies for Treating Cancer …
4 Sept 2008
No longer Director (1)
3 Sept 2008
No longer Director (1)
3 Jul 2008
Annual report for the year ending 31/03/2008
19 Jun 2008
Company statute
13 Jun 2008
Annual report for the year ending 31/12/2007
10 Jun 2008
Director: David Andrew Eatwell · No longer Director (1)
2 Jun 2008
No longer Director (1)
2 Jun 2008
Director: David Andrew Eatwell
15 May 2008
Company statute
7 May 2008
Company statute
10 Apr 2008
Patent: Verfahren mit Hohem Durchsatz zur Charakterisierung von Antikörpern
3 Apr 2008
Capital: 44.6M DKK · Company statute
2 Jan 2008
Company statute
31 Dec 2007
Balance sheet for 31/12/2007 · Earnings statement for 31/12/2007
19 Dec 2007
Patent: Antikörper Gegen CD38 zur Behandlung von Multiplem Myelom
23 Nov 2007
Capital: 44.5M DKK · Company statute
14 Nov 2007
Annual report for the year ending 30/09/2007
25 Oct 2007
Company statute
4 Oct 2007
Annual report for the year ending 30/06/2007
26 Sept 2007
Patent: Combination treatment of CD38-expressing tumors
26 Sept 2007
Patent: Combination Treatment of CD38-Expressing Tumors
25 Sept 2007
Wordmark: “HUMAX-CD4“
20 Sept 2007
Capital: 44.5M DKK · Company statute
13 Jul 2007
Annual report for the year ending 31/03/2007
9 Jul 2007
Company statute
7 Jun 2007
Capital: 44.5M DKK
9 May 2007
Company statute
2 May 2007
Member of the board: Burton G. Malkiel · Company statute
1 May 2007
Annual report for the year ending 31/12/2006
19 Apr 2007
Member of the board (1)
19 Feb 2007
Capital: 213,458 DKK
7 Feb 2007
Capital: 44.1M DKK · Company statute
31 Jan 2007
No longer Member of the board (1)
31 Jan 2007
No longer Member of the board (1)
25 Jan 2007
Patent: Potency-Tests für einen an einen FC-Rezeptor Bindenden Antikörper-Arzneistoff
3 Jan 2007
Company statute
31 Dec 2006
Balance sheet for 31/12/2006 · Earnings statement for 31/12/2006
5 Dec 2006
Capital: 39.6M DKK · Company statute
12 Nov 2006
Annual report for the year ending 30/09/2006
9 Nov 2006
Danish company filing
8 Nov 2006
Capital: 77,981 DKK
22 Sept 2006
Capital: 39.6M DKK
13 Sept 2006
Annual report for the year ending 30/06/2006
2 Aug 2006
Capital: 39.5M DKK · Company statute
6 Jul 2006
Company statute
7 Jun 2006
Capital: 39.4M DKK · Company statute
18 May 2006
Annual report for the year ending 31/03/2006
4 May 2006
Annual report for the year ending 31/12/2005
27 Apr 2006
Persons
26 Apr 2006
Company statute
23 Mar 2006
Patent: Antibodies Against CD38 for Treatment of Multiple Myeloma
23 Mar 2006
Patent: Antibodies Against CD38 for Treatment of Multiple Myeloma
8 Mar 2006
Capital: 39.2M DKK · Company statute
1 Feb 2006
Capital: 38.9M DKK · Company statute
31 Dec 2005
Balance sheet for 31/12/2005 · Earnings statement for 31/12/2005
13 Dec 2005
Articles of association amended on 1 December 2005.
2 Dec 2005
Capital: 33.1M DKK · Company statute
17 Nov 2005
Annual report for the year ending 30/09/2005
8 Nov 2005
Capital: 33.1M DKK · Company statute
3 Nov 2005
Patent: Humane Monoklonale Antikörper Gegen CD20
10 Oct 2005
Director (1) · Company statute
21 Sept 2005
Director (1)
31 Aug 2005
Capital: 33.1M DKK · Company statute
23 Aug 2005
Annual report for the year ending 30/06/2005
18 Aug 2005
Capital: 33.1M DKK · Company statute
15 Aug 2005
No longer Auditor: Deloitte Statsautoriseret A/S · Company statute
9 Aug 2005
No longer Director (1)
5 Aug 2005
No longer Director (1)
2 Aug 2005
Capital: 30.6M DKK · Company statute
23 Jun 2005
Director (1) · Capital: 30.5M DKK · Company statute
16 Jun 2005
Company statute
6 Jun 2005
Director (1)
31 May 2005
Annual report for the year ending 31/03/2005
12 May 2005
Capital: 30.3M DKK · Company statute
28 Apr 2005
Annual report for the year ending 31/12/2004
20 Apr 2005
No longer Auditor: Deloitte Statsautoriseret A/S
14 Mar 2005
Capital: 30.1M DKK · Company statute
10 Feb 2005
Capital: 30M DKK · Company statute
12 Jan 2005
Company statute
1 Aug 2003
No longer Director (1)
24 Apr 2003
No longer Chair of the board (1)
7 Mar 2002
Member of the board (1)
7 Mar 2002
No longer Member of the board (1)
7 Mar 2002
No longer Member of the board (1)
21 Jan 2002
No longer Director (1)
1 Oct 2001
Director (1)
19 Apr 2001
Auditor: Pricewaterhousecoopers Services Statsautoriseret A/S
22 Mar 2001
No longer Member of the board (1)
22 Mar 2001
Member of the board (1)
22 Mar 2001
No longer Auditor: Green IV ApS
22 Mar 2001
Auditor: Deloitte Statsautoriseret A/S
22 Mar 2001
No longer Auditor: Pricewaterhousecoopers Services Statsautoriseret A/S
25 Aug 2000
Auditor: Green IV ApS
27 Jul 2000
Director (1)
27 Jul 2000
Member of the board (1)
27 Jul 2000
No longer Member of the board (1)
25 Jul 2000
No longer Auditor: Deloitte Statsautoriseret A/S
25 Jul 2000
Auditor: Pricewaterhousecoopers Services Statsautoriseret A/S
21 Jul 2000
Member of the board (1)
21 Jul 2000
Member of the board (1)
2 Feb 2000
Member of the board (1)
22 Dec 1999
No longer Chair of the board (1)
25 Feb 1999
Director (1)
25 Feb 1999
Chair of the board (1)
25 Feb 1999
Director (1) · Member of the board (1)
25 Feb 1999
Member of the board (1)
25 Feb 1999
Auditor: Deloitte Statsautoriseret A/S
25 Feb 1999
No longer Auditor: EY Danmark A/S
15 Feb 1999
Chair of the board (1)
17 Nov 1998
No longer Chair of the board (1)
17 Nov 1998
No longer Director (1) · No longer Member of the board (1)
17 Nov 1998
No longer Member of the board (1)
17 Nov 1998
No longer Auditor: PricewaterhouseCoopers, Statsautoriseret Revisionsinteressentskab
17 Nov 1998
Auditor: EY Danmark A/S
11 Jun 1998
Chair of the board (1)
11 Jun 1998
Director (1) · Member of the board (1)
11 Jun 1998
Member of the board (1)
11 Jun 1998
Founder: G. A
11 Jun 1998
Auditor: PricewaterhouseCoopers, Statsautoriseret Revisionsinteressentskab
There are no publications matching your search.

Mentions

28 Sept 2026 in Rne
President: Genmab France SAS
1 May 2025 in Psc
Companies House - Persons with Significant Control
14 Dec 2024 in Hrdk
Genmab Germany GmbH: “Liste der Gesellschafter“
There are no publications matching your search.

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Printing is only available to North Data premium service subscribers.